Can you have PCOS at a normal weight?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Yes. PCOS is diagnosed on cycles, androgens and ovarian findings, not on body weight, and a large minority of women with PCOS have a BMI in the normal range. Insulin resistance can still be present at a normal BMI, which is why the 2023 international guideline asks for a 75 g glucose tolerance test regardless of BMI.
Body weight is not one of the diagnostic criteria for PCOS. The Rotterdam criteria are ovulatory dysfunction, hyperandrogenism and polycystic ovarian morphology, and none of them mention BMI. Women at a normal weight are frequently told they cannot have PCOS, which delays diagnosis by years. The 2023 International Evidence-based Guideline is explicit that its recommendations apply to women from lean to higher weight unless a BMI is specifically stated.
Insulin resistance at a normal BMI
A normal BMI does not rule out insulin resistance in PCOS. This is why the guideline recommends the 75 g oral glucose tolerance test as the most accurate assessment of glycaemic status in PCOS "regardless of BMI", rather than reserving it for women above a weight threshold. It is also why lipids are recommended at diagnosis in all women with PCOS regardless of age and BMI. A slim woman with PCOS and a two hour glucose of 165 mg/dL has the same problem as a heavier woman with the same number.
How it usually presents
In women at a normal weight, PCOS more often shows up as long or absent cycles, difficulty conceiving, acne along the jawline, or hair growth, without the visible metabolic signs people associate with the condition. Because the outward picture is different, the workup is sometimes shortened to a pelvic ultrasound and stopped there. The same tests belong: total and free testosterone by mass spectrometry, 17-hydroxyprogesterone, prolactin, TSH and an oral glucose tolerance test.
Does treatment differ
Some of it does. Lifestyle recommendations in the guideline focus on overall health and prevention of weight gain rather than weight loss when weight is already in a healthy range. Metformin is recommended in adults with PCOS and a BMI of 25 kg/m2 or above, and may be considered at a lower BMI with the guideline noting limited evidence there. The combined oral contraceptive pill, anti-androgens for hirsutism and letrozole for ovulation induction are used the same way at any BMI.
| Element of care | Normal BMI | Higher BMI |
|---|---|---|
| Diagnostic criteria | Identical | Identical |
| 75 g OGTT | Recommended | Recommended |
| Metformin | May be considered, limited evidence | Recommended at BMI 25 or above |
| Letrozole for ovulation induction | First line | First line |
If you have been told your weight rules out PCOS, ask for the diagnosis to be worked up on the criteria rather than on appearance. Cycle history, androgens measured off the pill, and a glucose tolerance test will settle it.
The clinical detail
PCOS prevalence is 10 to 13 per cent globally using Rotterdam criteria, similar across regions and ethnicities, with the 2023 guideline noting possibly higher rates in South East Asian and Eastern Mediterranean populations. The guideline population statement reads that recommendations include women from lean to higher weight unless a BMI is specified.
Practical testing points at a normal BMI: measure androgens off any combined oral contraceptive for at least three months, since ethinylestradiol raises sex hormone binding globulin and falsely normalises free testosterone. Use calculated free androgen index rather than a direct free testosterone immunoassay. An oral glucose tolerance test with paired insulin values often shows the pattern that a fasting glucose and HbA1c miss entirely, though insulin levels themselves have no validated diagnostic cut-off.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. PMID 37580314
- About Polycystic Ovary Syndrome (PCOS). NICHD, National Institutes of Health
- Polycystic ovary syndrome: an update on diagnosis and management (2026). Cleveland Clinic Journal of Medicine
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.